Positive cross-regulatory loop ties GATA-3 to estrogen receptor α expression in breast cancer

Cancer Research

Volumn 67, Issue 13, 2007, Pages 6477-6483

  Eeckhoute, Jérôme ^d   Keeton, Erika Krasnickas ^b   Lupien, Mathieu ^d   Krum, Susan A ^d   Carroll, Jason S ^c   Brown, Myles ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b ASTRAZENECA   (United Kingdom)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR ALPHA; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; RNA POLYMERASE II; TRANSCRIPTION FACTOR GATA 3;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CELL CYCLE PROGRESSION; CELL STRAIN MCF 7; CELL TYPE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; ESTROGEN ACTIVITY; FEEDBACK SYSTEM; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOREGULATION; IMMUNOSTIMULATION; PHENOTYPE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION;

BREAST NEOPLASMS; CELL LINE, TUMOR; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; GATA3 TRANSCRIPTION FACTOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HEPATOCYTE NUCLEAR FACTOR 3-ALPHA; HUMANS; MODELS, BIOLOGICAL; MODELS, GENETIC; NEOPLASMS, HORMONE-DEPENDENT; PROMOTER REGIONS (GENETICS); RNA POLYMERASE II; TRANSCRIPTION, GENETIC;

EID: 34447130861     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-0746     Document Type: Article

References (53)

1. Kanavos P. The rising burden of cancer in the developing world. Ann Oncol 2006;17 Suppl 8:viii15-23.
2. Dahlman-Wright K, Cavailles V, Fuqua SA, et al. International Union of Pharmacology. LXIV. Estrogen receptors. Pharmacol Rev 2006;58:773-81.
3. Doisneau-Sixou SF, Sergio CM, Carroll JS, Hui R, Musgrove EA, Sutherland RL. Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells. Endocr Relat Cancer 2003;10:179-86.
4. West M, Blanchette C, Dressman H, et al. Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci U S A 2001;98:11462-7.
5. van 't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
6. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003;100:8418-23.
7. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
8. Gruvberger S, Ringner M, Chen Y, et al. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 2001;61:5979-84.
9. Lacroix M, Leclercq G. About GATA3, HNF3A, and XBP1, three genes co-expressed with the oestrogen receptor-α gene (ESR1) in breast cancer. Mol Cell Endocrinol 2004;219:1-7.
10. Merika M, Orkin SH. DNA-binding specificity of GATA family transcription factors. Mol Cell Biol 1993;13:3999-4010.
11. Ko LJ, Engel JD. DNA-binding specificities of the GATA transcription factor family. Mol Cell Biol 1993;13:4011-22.
12. Lee HJ, Takemoto N, Kurata H, et al. GATA-3 induces T helper cell type 2 (Th2) cytokine expression and chromatin remodeling in committed Th1 cells. J Exp Med 2000;192:105-15.
13. Zhu J, Yamane H, Cote-Sierra J, Guo L, Paul WE. GATA-3 promotes Th2 responses through three different mechanisms: induction of Th2 cytokine production, selective growth of Th2 cells and inhibition of Th1 cell-specific factors. Cell Res 2006;16:3-10.
14. Pandolfi PP, Roth ME, Karis A, et al. Targeted disruption of the GATA3 gene causes severe abnormalities in the nervous system and in fetal liver haematopoiesis. Nat Genet 1995;11:40-4.
15. Lim KC, Lakshmanan G, Crawford SE, Gu Y, Grosveld F, Engel JD. Gata3 loss leads to embryonic lethality due to noradrenaline deficiency of the sympathetic nervous system. Nat Genet 2000;25:209-12.
16. Asselin-Labat ML, Sutherland KD, Barker H, et al. Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nat Cell Biol 2007;9:201-9.
17. Kouros-Mehr H, Slorach EM, Sternlicht MD, Werb Z. GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. Cell 2006;127:1041-55.
18. Mallepell S, Krust A, Chambon P, Brisken C. Paracrine signaling through the epithelial estrogen receptor α is required for proliferation and morphogenesis in the mammary gland. Proc Natl Acad Sci U S A 2006;103:2196-201.
19. Parikh P, Palazzo JP, Rose LJ, Daskalakis C, Weigel RJ. GATA-3 expression as a predictor of hormone response in breast cancer. J Am Coll Surg 2005;200:705-10.
20. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-74.
21. Mehra R, Varambally S, Ding L, et al. Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis. Cancer Res 2005;65:11259-64.
22. Keeton EK, Brown M. Cell cycle progression stimulated by tamoxifen-bound estrogen receptor-α and promoter-specific effects in breast cancer cells deficient in N-CoR and SMRT. Mol Endocrinol 2005;19:1543-54.
23. Eeckhoute J, Carroll JS, Geistlinger TR, Torres-Arzayus MI, Brown M. A cell-type-specific transcriptional network required for estrogen regulation of cyclin D1 and cell cycle progression in breast cancer. Genes Dev 2006;20:2513-26.
24. Labhart P, Karmakar S, Salicru EM, et al. Identification of target genes in breast cancer cells directly regulated by the SRC-3/AIB1 coactivator. Proc Natl Acad Sci U S A 2005;102:1339-44.
25. Lacroix M, Leclercq G. Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res Treat 2004;83:249-89.
26. Hall JM, Korach KS. Stromal cell-derived factor 1, a novel target of estrogen receptor action, mediates the mitogenic effects of estradiol in ovarian and breast cancer cells. Mol Endocrinol 2003;17:792-803.
27. Petz LN, Ziegler YS, Schultz JR, Kim H, Kemper JK, Nardulli AM. Differential regulation of the human progesterone receptor gene through an estrogen response element half site and Sp1 sites. J Steroid Biochem Mol Biol 2004;88:113-22.
28. Weisz A, Bresciani F. Estrogen regulation of protooncogenes coding for nuclear proteins. Crit Rev Oncog 1993;4:361-88.
29. Liu Y, Ludes-Meyers J, Zhang Y, et al. Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth. Oncogene 2002;21:7680-9.
30. Kos M, Reid G, Denger S, Gannon F. Minireview: genomic organization of the human ERα gene promoter region. Mol Endocrinol 2001;15:2057-63.
31. Carroll JS, Meyer CA, Song J, et al. Genome-wide analysis of estrogen receptor binding sites. Nat Genet 2006;38:1289-97.
32. Castles CG, Oesterreich S, Hansen R, Fuqua SA. Auto-regulation of the estrogen receptor promoter. J Steroid Biochem Mol Biol 1997;62:155-63.
33. Piva R, Bianchini E, Kumar VL, Chambon P, del Senno L. Estrogen induced increase of estrogen receptor RNA in human breast cancer cells. Biochem Biophys Res Commun 1988;155:943-9.
34. Ogryzko VV, Schiltz RL, Russanova V, Howard BH, Nakatani Y. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 1996;87:953-9.
35. Ciurciu A, Komonyi O, Pankotai T, Boros IM. The Drosophila histone acetyltransferase gcn5 and transcriptional adaptor ada2a are involved in nucleosomal histone h4 acetylation. Mol Cell Biol 2006;26:9413-23.
36. Kimura A, Horikoshi M. Tip60 acetylates six lysines of a specific class in core histones in vitro. Genes Cells 1998;3:789-800.
37. Valls E, Sanchez-Molina S, Martinez-Balbas MA. Role of histone modifications in marking and activating genes through mitosis. J Biol Chem 2005;280:42592-600.
38. Peterson CL, Laniel MA. Histones and histone modifications. Curr Biol 2004;14:R546-51.
39. Bulger M, Groudine M. Looping versus linking: toward a model for long-distance gene activation. Genes Dev 1999;13:2465-77.
40. Wang Q, Carroll JS, Brown M. Spatial and temporal recruitment of androgen receptor and its coactivators involves chromosomal looping and polymerase tracking. Mol Cell 2005;19:631-42.
41. Pennacchio LA, Ahituv N, Moses AM, et al. In vivo enhancer analysis of human conserved non-coding sequences. Nature 2006;444:499-502.
42. Crawford GE, Davis S, Scacheri PC, et al. DNase-chip: a high-resolution method to identify DNase I hypersensitive sites using tiled microarrays. Nat Methods 2006;3:503-9.
43. Sabo PJ, Kuehn MS, Thurman R, et al. Genome-scale mapping of DNase I sensitivity in vivo using tiling DNA microarrays. Nat Methods 2006;3:511-8.
44. Hawkins RD, Ren B. Genome-wide location analysis: insights on transcriptional regulation. Hum Mol Genet 2006;15 Spec No 1:R1-7.
45. Hatzis P, Talianidis I. Dynamics of enhancer-promoter communication during differentiation-induced gene activation. Mol Cell 2002;10:1467-77.
46. Carroll JS, Liu XS, Brodsky AS, et al. Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell 2005;122:33-43.
47. Blobel GA, Sieff CA, Orkin SH. Ligand-dependent repression of the erythroid transcription factor GATA-1 by the estrogen receptor. Mol Cell Biol 1995;15:3147-53.
48. Bresnick EH, Martowicz ML, Pal S, Johnson KD. Developmental control via GATA factor interplay at chromatin domains. J Cell Physiol 2005;205:1-9.
49. Rosenfeld MG, Lunyak VV, Glass CK. Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response. Genes Dev 2006;20:1405-28.
50. Kyrmizi I, Hatzis P, Katrakili N, Tronche F, Gonzalez FJ, Talianidis I. Plasticity and expanding complexity of the hepatic transcription factor network during liver development. Genes Dev 2006;20:2293-305.
51. Ferrer J. A genetic switch in pancreatic β-cells: implications for differentiation and haploinsufficiency. Diabetes 2002;51:2355-62.
52. Manuylov NL, Smagulova FO, Tevosian SG. Fog2 excision in mice leads to premature mammary gland involution and reduced Esr1 gene expression. Oncogene 2007; doi: 10.1038/sj.onc.1210333.
53. Odom DT, Dowell RD, Jacobsen ES, et al. Core transcriptional regulatory circuitry in human hepatocytes. Mol Syst Biol 2006;2:2006.0017. Epub 2006 May 2.